Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytisine Single Dose-Escalation in Smokers
NCT03848208Phase 1Completed
- Sponsor
- Achieve Life Sciences
- Start
- Feb 2019
- Primary completion
- Sep 2019
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cytisinicline in nicotine dependence (18 arms), sponsored by Achieve Life Sciences. Primary endpoints: Treatment-Emergent Adverse Events at Day 6, Maximum Observed Plasma Concentration at Day 1 and 1 more. Started Feb 2019; status: completed.
02
Drugs
cytisinicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT03848208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03848208.